Estimating TP53 Mutation Carrier Probability in Families with Li–Fraumeni Syndrome Using LFSPRO
暂无分享,去创建一个
David M. Thomas | L. Strong | S. Savage | A. Blackford | M. Ballinger | Wenyi Wang | P. Mai | Gang Peng | Jialu Li | J. Bojadzieva | G. Peng
[1] David M. Thomas,et al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. , 2016, The Lancet. Oncology.
[2] J. Lancaster,et al. Abstract PD7-03: Characterization of Li-Fraumeni syndrome diagnosed using a 25-gene hereditary cancer panel , 2016 .
[3] K. Nichols,et al. Diagnostic Performance of Whole-Body MRI as a Tool for Cancer Screening in Children With Genetic Cancer-Predisposing Conditions. , 2015, AJR. American journal of roentgenology.
[4] C. Bonaïti‐pellié,et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] David M. Thomas,et al. High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort , 2013, PloS one.
[6] J. Beyene,et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.
[7] David M. Thomas,et al. Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis , 2010, Clinical Cancer Research.
[8] Giovanni Parmigiani,et al. Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. , 2010, Cancer research.
[9] Catherine Bonaïti-Pellié,et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Malkin,et al. High frequency of de novo mutations in Li–Fraumeni syndrome , 2009, Journal of Medical Genetics.
[11] S. Sommer,et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Parmigiani,et al. Multiple diseases in carrier probability estimation: Accounting for surviving all cancers other than breast and ovary in BRCAPRO , 2008, Statistics in medicine.
[13] Giovanni Parmigiani,et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Parmigiani,et al. Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomothearapy , 2009, Radiation oncology.
[15] S. Shete,et al. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. , 2006, Cancer research.
[16] D. Easton,et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.
[17] Karl W Broman,et al. BayesMendel: an R Environment for Mendelian Risk Prediction , 2004, Statistical applications in genetics and molecular biology.
[18] R. Eeles,et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.
[19] Shih-Jen Hwang,et al. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. , 2003, American journal of human genetics.
[20] P. Pharoah,et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history , 2003, The Lancet.
[21] G. Lenoir,et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. , 2002, Journal of the National Cancer Institute.
[22] J. Fraumeni,et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[23] C. Bonaïti‐pellié,et al. Sensitivity and predictive value of criteria for p53germline mutation screening , 2001, Journal of medical genetics.
[24] A. Craft,et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.
[25] L. Strong,et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. , 1992, American journal of human genetics.
[26] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[27] W. Blattner,et al. A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.
[28] R. Elston,et al. A general model for the genetic analysis of pedigree data. , 1971, Human heredity.
[29] J. Fraumeni,et al. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. , 1969, Journal of the National Cancer Institute.
[30] J. Fraumeni,et al. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.
[31] R. Nussbaum,et al. Genetic/familial high-risk assessment: breast and ovarian. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[32] S. Shete,et al. Effects of measured susceptibility genes on cancer risk in family studies , 2009, Human Genetics.
[33] D. Berry,et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.
[34] R. Eeles. Germline mutations in the TP53 gene. , 1995, Cancer surveys.
[35] A. Chakravarti,et al. Segregation analysis of 159 soft tissue sarcoma kindreds: Comparison of fixed and sequential sampling schemes , 1992, Genetic epidemiology.
[36] L. Strong,et al. The genetic implications of long-term survival of childhood cancer. A conceptual framework. , 1987, The American journal of pediatric hematology/oncology.